New Trial Results: Kiora's KIO-301 Demonstrates Meaningful Vision Improvements in Retinitis Pigmentosa

Improving sight in patients with severe vision loss

Developing therapeutics for patients with orphan retinal diseases

Find out more about our therapies

Kiora Pharmaceuticals, Inc. (Kiora) is a clinical development-stage company focusing on novel therapeutics for the treatment of orphan retinal diseases with high unmet need. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.

Learn more about our company
In the Pipeline
Loading RSS Feed